Atopic Dermatitis

A growing body of research is dedicated to understanding how various climatic elements impact AD.

Explore the disease progression of atopic dermatitis and strategies to make a difference in patients' lives.

The study focused on the use of Internet resources, number of medical consultations, and factors influencing treatment outcomes.

This article represents the first time the news has been shared with the public. Turn's Founder and CEO, Bradley Burnam, shares details.

Data from a retrospective analysis demonstrated that patients with moderate to severe alopecia areata are at a higher risk of developing atopic dermatitis compared to those with mild alopecia areata.

Learn more about the in-depth topics covered in the July 2024 supplement of Dermatology Times.

Generation Z patients had lower atopic dermatitis severity but similar disease perception compared to Millennial patients.

Approved down to the age of 6, the treatment is covered by 2 pharmacy benefit manager contracts to provide timely coverage.

A recent study saw a “significant” decrease in allergen-specific IgE levels over a 1-year period of dupilumab therapy in children with atopic dermatitis.

Robert Posnick, MD, hosted a Case-Based Roundtable discussion to review 2 challenging cases of atopic dermatitis involving hyperpigmentation and alopecia areata.

Linda Stein Gold, MD, reviews data presented at SPD and elaborates on study design, methodology, and results.

Mona Shahriari, MD, hosted a Case-Based Roundtable discussion to review 2 challenging cases of atopic dermatitis in patients with skin of color.

Jenny Murase, MD, and Elizabeth Kiracofe, MD, highlighted key clinical considerations to optimize atopic dermatitis care for patients during pregnancy, prepregnancy, postpartum, and breastfeeding.

Tapinarof cream 1% has proven to be an effective and safe treatment for atopic dermatitis in diverse populations, according to a poster presented at the SPD's annual meeting.

A significant proportion of pediatric patients with AD achieved and maintained clinical remission with dupilumab, according to a poster presented at the SPD's annual meeting.

Lio discusses his SPD 2024 non-CME talk, new and exciting innovations in pediatric atopic dermatitis, and more.

Learn more about the latest research in atopic dermatitis from Raj Chovatiya, MD, PhD, MSCI; Robert Sidbury, MD; David Rosmarin, MD; Amy Paller, MD; Melinda Gooderham, MD, MSc, FRCPC; and Jonathan Silverberg, MD, PhD, MPH.

Looking to the future of atopic dermatitis treatment, Drs Kiracofe and Murase offer concluding remarks on current unmet needs, the benefits of treatment guidelines, and the importance of treating itch in patients who are or may become pregnant.

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, have a comprehensive discussion on treatment safety considerations for patients with atopic dermatitis who are breastfeeding.

Alexandra Golant, MD, reviewed the complexities of managing atopic dermatitis with a focus on hand and foot involvement.

Researchers not only confirmed the rapid and sustained efficacy of the drug, but also observed an increased onset of action for children under 6.

Patrick Burnett, MD, PhD, provides insights into the significance of Arcutis’ roflumilast cream 0.15% formulation and its impact on pediatric patients.

Click here to answer today's poll and read more about OX40 treatment for atopic dermatitis.

The planned PDUFA data was July 7, 2024.